Reported 27 days ago
Eli Lilly and Company (LLY) saw its stock fall in premarket trading after reporting third quarter results that fell short of revenue expectations, largely due to disappointing sales of its weight loss drug, Zepbound. The company also reduced its profit forecast for the year.
Source: YAHOO